Actinogen Medical - XanaCIDD study in MDD now underway
Actinogen announced that the first patient was randomised and treated in its XanaCIDD Phase II study in major depressive disorder (MDD) assessing...
671 Views
Actinogen Medical - Cognitive enhancer targeting key diseases
Actinogen Medical is developing its lead asset, small molecule Xanamem, a selective 11β-HSD1 inhibitor designed to cross the blood-brain barrier...
661 Views
Actinogen Medical - Cognitive enhancer targeting key diseases
Actinogen’s share price has experienced a rather volatile period since May 2019, when it decreased c 70% following the disappointing Phase II...
671 Views
Actinogen Medical - Executive interview
Actinogen Medical is an ASX-listed biotech developing its lead asset Xanamem, a specific 11β-HSD1 inhibitor designed to treat cognitive impairment...
673 Views
Actinogen Medical - Well-timed XanaHES study saves the day
Actinogen’s share price has experienced a rather volatile period since May 2019, when it decreased c 70% following the disappointing Phase II...
1.1k Views